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Abstract 
Objective: To evaluate fetal libronectin as a screening test for premature delivery in asymptomatic women with multi- 
ple pregnancies. Method: In the mid-second trimester, the concentrations of fetal tibronectin in the cervical and vaginal 
secretions of 68 patients with multiple gestations were sampled weekly by monoclonal antibody immunoassay in order 
to predict preterm labor. Results: The results for the prediction of preterm labor differ according to whether we con- 
sider a single positive result (fetal libronectin > 50 @ml) as predictive of preterm labor or whether we only consider 
at least two consecutive positive results as predictive of preterm labor. The fetal tibronectin test had a sensitivity for 
preterm birth before 37 weeks of 90.9% and 86.6%, respectively, with a specificity of 68.5% vs. 78.9% and positive and 
negative values of 73.1% vs. 76.4% and 88.8% vs. 88.2%, respectively. Similar results were obtained for preterm birth 
before 34 weeks. Conclusion: In a condition such as multiple pregnancy which is already at risk for premature delivery 
the possibility of raising the specificity of the test with virtually no decrease in sensitivity guarantees better recognition 
of patients likely to develop premature labor. This possibility can be achieved simply by considering two positive con- 
secutive samples as predictive of pretenn labor. 
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1. Introduction 
In multiple pregnancies there is an increased in- 
cidence of polyhydramnios, gestosis, anemia and 
preterm delivery. The main complication in these 
cases is preterm delivery, since it represents a life- 
threatening situation for the twins. 
* Corresponding author, Fax: +39 81 7462903. 
It has been calculated that the mean duration of 
twin pregnancies is 37 weeks. In other words, 
about half of these pregnancies are delivered 
before 37 weeks. Moreover the risk linked with 
prematurity is increased by the low birth weight of 
the twins in comparison with that of single fetuses 
of the same gestational age [l]. 
Premature birth, defined as delivery before 37 
complete weeks of gestation, is the leading cause of 
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perinatal mortality and short- and long-term fetal 
morbidity. Most of the morbidity and mortality at- 
tributed to preterm birth occur in births before 34 
weeks of gestation [ 11. 
Various strategies have been used to lower this 
incidence including risk screening during the peri- 
natal period, patient education, monitoring of 
uterine activity, long-term tocolysis, perinatal 
home nursing care and early prenatal care. How- 
ever obstetric management could be more effective 
if women at risk for this condition could be iden- 
tified by the early use of a biochemical marker. 
Recently some authors [2-41, in a multicenter 
cross- sectional study of symptomatic women with 
suspected preterm labor, demonstrated that detec- 
tion of fetal libronectin in cervical and vaginal 
secretions identified pregnant women at high risk 
for preterm delivery. These authors postulated 
that because fetal libronectin is a component of 
the extracellular matrix of the fetal membranes 
and is normally present in amniotic fluid and 
placental tissue, its appearance in the cervix and 
vagina is suggestive of mechanical or 
inflammation-mediated damage to the mem- 
branes. 
The objective of this study was to evaluate fetal 
fibronectin as a screening test for premature deliv- 
ery in multiple pregnancies. 
2. Materials and methods 
We evaluated the presence of fetal libronectin in 
the cervical and vaginal secretions of 68 con- 
secutive asymptomatic women with multiple gesta- 
tions (two or more fetuses) presenting at our 
centers. Six of the 68 pregnancies were triplets 
(8.8%). 
Documentation of the intact membranes and 
undilated cervix was performed at the start of the 
study. Gestational age was calculated on the basis 
of the last menstrual period and early vaginal ul- 
trasonography. Informed consent was obtained 
from each patient at recruitment. 
The study started in the mid-second trimester 
(24 weeks). Cervical and vaginal secretions, both 
from the posterior vaginal fornix and from the ex- 
ternal cervical ostium, were sampled weekly using 
a sterile speculum. The samples were collected 
using sterile dacron swabs and analyzed im- 
mediately for the presence of fetal fibronectin. 
The presence of fetal libronectin was determined 
qualitatively using a commercial kit based on a 
monoclonal antibody specifically recognizing fetal 
fibronectin (Fetal Fibronectin Membrane Im- 
munoassay; Adeza Biomedical, Sunnyvale, USA) 
[5,6]. A sample was defined as positive if its absor- 
bance was greater than that of the positive control 
(50 rig/ml). 
We then evaluated reliability by a different 
method, considering first a positive result obtained 
on one single occasion, and then a positive result 
obtained on at least two consecutive occasions. 
The reliability of this assay in predicting preterm 
labor was evaluated by means of the classic par- 
ameters of sensitivity, specificity and predictive 
values. 
Categoric clinical data were evaluated by rela- 
tive risk ratios and the X2-test; P < 0.01 was con- 
sidered to be statistically significant. 
3. Results 
Sixty-eight pregnant women with multiple preg- 
nancies were examined. Thirty-three (48.5%) 
delivered before 37 weeks and 35 (5 1 So/) delivered 
after 37 weeks of gestation. No patient was 
delivered before 37 weeks for reasons other than 
preterm labor or preterm rupture of the mem- 
branes. There were no statistical differences in ma- 
ternal age, parity or history of prior preterm birth 
between the women delivered before or after 37 
weeks. 
The results of our study differ according to 
whether we considered a positive result obtained 
from a single sample or one obtained from at least 
two consecutive samples. 
If we take the first case (i.e. a single positive 
sample), the sensitivity of fetal llbronectin was 
90.9%, the specificity was 68.5%, the positive pre- 
dictive value was 73.1% and the negative predictive 
value was 88.8% for the prediction of delivery 
before 37 weeks (Table 1). The relative risk of 
preterm delivery for one positive fetal tibronectin 
result was 6.57 (95% C.I. 4.80-77.59, X2-test 
22.67, P < 0.000001). 
If we take a positive result from at least two con- 
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Table 1 
Reliability of fetal fibronectin in predicting delivery before 37 
weeks from a single positive sample 
Multiple pregnancy Fetal Fetal Total 
tibronectin iibronectin 
positive negative 
Delivery 
<37 weeks 30 3 33 
>37 weeks 11 24 35 
Total 41 27 68 
Sensitivity 90.9%, specificity 68.5%, positive predictive value 
73.1%. negative predictive value 88.8%, relative risk 6.57 (95% 
C.I. 4.80-77.59). &test 22.67, P < O.OOOOO1. 
secutive samples, the sensitivity of fetal Iibronectin 
was 86.6%, but the specificity increased to 78.9%, 
with a positive and a negative predictive value of 
76.4% and 88.2%, respectively, for the prediction 
of delivery before 37 weeks (Table 2). The relative 
risk of a preterm delivery was 6.52 (95% C.I. 
5.71-115.67, X2-test 26.3, P < O.OflOOOl). 
The reliability of this test in true preterm births, 
i.e. those delivered before 34 weeks, showed 
similar results (Tables 3 and 4). 
When using a single positive sample for diagno- 
sis, the mean time of diagnosis (f SD.) was 
25.7 f 1.8 weeks. When using two consecutive 
positive samples for diagnosis, the mean time was 
27.1 * 2.1 weeks. In either case the mean time of 
diagnosis was sufficient to begin an intervention 
program in those patients shown to be at high risk. 
Our data show a clear difference, although not sig- 
Table 2 
Reliability of fetal fibronectin in predicting delivery before 37 
weeks from two consecutive positive samples 
Multiple pregnancy Fetal Fetal Total 
fibronectin fibronectin 
positive negative 
Delivery 
<37 weeks 26 4 30 
z-37 weeks 8 30 38 
Total 34 34 68 
Sensitivity 86.6%, specificity 78.9%. positive predictive value 
76.4%. negative predictive value 88.2%. relative risk 6.52 (95% 
C.I. 5.71-115.67). X2-test 26.3, P < O.GQOOO1. 
Table 3 
Reliability of fetal fibronectin in predicting delivery before 34 
weeks from a single positive sample 
Multiple pregnancy Fetal Fetal Total 
fibronectin fibronectin 
positive negative 
Delivery 
< 34 weeks 
> 34 weeks 
Total 
14 I 15 
18 35 53 
32 36 68 
Sensitivity 93.3%, specificity 66.0%, positive predictive value 
37.8%, negative predictive value 96.7%, relative risk 27.22 (95% 
C.I. 3.23-151.39). X2-test 14.24, P < 0.0001. 
n&ant, between the mean interval from obtaining 
a positive result to delivery (Table 5). 
4. Discussion 
The significant increase in perinatal mortality 
and morbidity in multiple gestations in com- 
parison with single gestations depends on the 
higher incidence of preterm birth. Indeed 50% of 
twins are preterm and those born before 34 weeks 
have a still higher risk of complications. 
In the last 20 years a number of protocols have 
been proposed for the prevention of preterm labor, 
such as bed rest, prophylactic cerclage and the 
prophylactic administration of /3-mimetics and 
progestatives [7]. 
Objective signs of impending preterm delivery 
such as cervical modifications and uterine contrac- 
Table 4 
Reliability of fetal tibronectin in predicting delivery before 34 
weeks from two consecutive positive samples 
Multiple pregnancy Fetal Fetal Total 
fibronectin tibronectin 
positive negative 
Delivery 
< 34 weeks 10 1 11 
> 34 weeks 13 44 57 
Total 23 45 68 
Sensitivity 90.90/o, soecificitv 77.1%. oositive oredictive value 
38.4%. negative predictive v&e 97.6%, relative’ risk 33.84 (95% 
C.I. 3.75-188.23), x2-test 16.18, P < 0.0005. 
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Table 5 
Comparison of the positive sample-delivery interval between 
the two groups 
Single posi- Two con- 
tive sample secutive posi- 
tive samples 
No. of patients 
Sample-delivery 
interval Idavsb 
32 21 
54 l 31 43 * 39 P < 0.05 
tions have shown a sensitivity and specificity of 
less than 45%. Vaginal pH has a higher sensitivity 
but its specificity is very poor [4-81. Less reliable 
indicators are obstetric anamnesis, demographic 
factors and obstetric risk factors [4,9]. 
The first evaluation of the effectiveness of fetal 
tibronectin content in cervical and vaginal secre- 
tions in predicting preterm delivery was performed 
by Lockwood et al. [4]. They studied 117 pregnant 
women between 24 and 37 weeks’ gestation with 
uterine contractions or precocious cervical 
modifications, comparing fetal libronectin levels 
with gestational age at the time of onset of labor 
[4]. They were able to demonstrate the clinical ef- 
fectiveness of fetal libronectin in predicting 
preterm delivery in symptomatic patients. 
Morrison et al. [lo] evaluated fetal fibronectin 
vaginal and cervical levels in 28 pregnant women 
between 24 and 34 weeks’ gestation with regular 
uterine contractions (> 10/h), with unruptured 
membranes and a cervical dilatation I 1 cm. Cer- 
vical fetal fibronectin levels > 50 rig/ml identified 
patients with preterm labor who subsequently had 
a preterm delivery, with a sensitivity of 90%, a 
specificity of 72%, a positive predictive value of 
64% and a negative predictive value of 93%. 
In the present study a single positive test for the 
presence of fetal fibronectin in the cervical and 
vaginal secretions of women with multiple gesta- 
tions was predictive of preterm delivery before 37 
weeks’ gestation with a sensitivity of 90.9% and a 
specificity of 68.5%. If at least two positive con- 
secutive samples were considered diagnostic, the 
sensitivity was 86.6% and the specificity was 
78.9%. This means that in a condition that is al- 
ready at risk for premature delivery such as multi- 
ple pregnancy the specificity of the test can be 
raised with virtually no decrease in sensitivity, 
guaranteeing a better recognition of patients likely 
to go into premature labor. 
Our results show that serial determinations of 
cervical and vaginal fetal libronectin levels are pre- 
dictive of preterm delivery in an asymptomatic risk 
group such as women with multiple pregnancies. 
The presence of fetal fibronectin in cervical and 
vaginal secretions in the second or third trimester 
may identify women with multiple gestations who 
are still asymptomatic but at high risk for preterm 
labor. Identification of these patients could lead to 
an early therapeutic approach such as bed rest, ad- 
ministration of tocolytic agents, patient education, 
perinatal monitoring with tocodynamometry and 
home nursing care, all of which may preclude early 
onset of labor [11,12]. 
Additional work needs to be carried out to con- 
firm these results and to determine whether fetal 
tibronectin is present in cervical and vaginal secre- 
tions before uterine contractions become appar- 
ent. In addition, future studies may better evaluate 
the time interval between a positive test and the 
beginning of preterm labor. In this way the test 
could also be useful for calculating induction of 
labor. 
From our data we can conclude that in multiple 
pregnancies a biochemical marker such as fetal 
tibronectin could be considered a useful tool in 
clinical practice for the early identification of pa- 
tients likely to develop preterm labor. 
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